Terms: = Leukemia AND ACVR1, SKR1, 90, ENSG00000115170, Q04771, ACVRLK2, FOP, ALK2, ACTRI AND Staging
51 results:
1. Role of social status and social environment on net survival in patients with chronic lymphocytic leukemia: A high-resolution population-based study.
Delapierre B; Troussard X; Damaj G; Dejardin O; Tron L
Cancer Epidemiol; 2023 Feb; 82():102292. PubMed ID: 36410088
[TBL] [Abstract] [Full Text] [Related]
2. [Mid-term efficacy of China Net Childhood Lymphoma-mature B-cell lymphoma 2017 regimen in the treatment of pediatric Burkitt lymphoma].
Zhang M; Wu P; Duan YL; Jin L; Yang J; Huang S; Liu Y; Hu B; Zhai XW; Wang HS; Fu Y; Li F; Yang XM; Liu AS; Qin S; Yuan XJ; Dong YS; Liu W; Zhou JW; Zhang LP; Jia YP; Wang J; Qu LJ; Dai YP; Guan GT; Sun LR; Jiang J; Liu R; Jin RM; Wang ZJ; Wang XG; Zhang BX; Chen KL; Zhuang SQ; Zhang J; Zhou CJ; Gao ZF; Zheng MC; Zhang Y
Zhonghua Er Ke Za Zhi; 2022 Oct; 60(10):1011-1018. PubMed ID: 36207847
[No Abstract] [Full Text] [Related]
3. IRF8 is a Reliable Monoblast Marker for Acute Monocytic leukemias.
Katz SG; Edappallath S; Xu ML
Am J Surg Pathol; 2021 Oct; 45(10):1391-1398. PubMed ID: 34172624
[TBL] [Abstract] [Full Text] [Related]
4. Second Malignancies after Radiation Therapy: Update on Pathogenesis and Cross-sectional Imaging Findings.
Khanna L; Prasad SR; Yedururi S; Parameswaran AM; Marcal LP; Sandrasegaran K; Tirumani SH; Menias CO; Katabathina VS
Radiographics; 2021; 41(3):876-894. PubMed ID: 33891523
[TBL] [Abstract] [Full Text] [Related]
5. A prognostic survival model based on metabolism-related gene expression in plasma cell myeloma.
Huang HY; Wang Y; Wang WD; Wei XL; Gale RP; Li JY; Zhang QY; Shu LL; Li L; Li J; Lin HX; Liang Y
Leukemia; 2021 Nov; 35(11):3212-3222. PubMed ID: 33686197
[TBL] [Abstract] [Full Text] [Related]
6. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
Usmani SZ; Hoering A; Ailawadhi S; Sexton R; Lipe B; Hita SF; Valent J; Rosenzweig M; Zonder JA; Dhodapkar M; Callander N; Zimmerman T; Voorhees PM; Durie B; Rajkumar SV; Richardson PG; Orlowski RZ;
Lancet Haematol; 2021 Jan; 8(1):e45-e54. PubMed ID: 33357482
[TBL] [Abstract] [Full Text] [Related]
7. Predictive impact of circulating microRNA-193a-5p on early relapse after autologous stem cell transplantation in patients with multiple myeloma.
Park SS; Lim JY; Kim TW; Ko YH; Jeon WJ; Lee SY; Lee JH; Min CK
Br J Haematol; 2020 May; 189(3):518-523. PubMed ID: 32030736
[TBL] [Abstract] [Full Text] [Related]
8. [Clinical analysis of a modified LMB89 Group C regimen in the treatment of pediatric high-risk Burkitt lymphoma].
Zhang M; Jin L; Yang J; Duan YL; Huang S; Zhou CJ; Zhang YH
Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):633-638. PubMed ID: 31495128
[No Abstract] [Full Text] [Related]
9. High prevalence of pulmonary findings in computed tomographies of HTLV-1-infected patients with and without adult-T cell leukemia/lymphoma - implications for staging.
Acuna-Villaorduna A; Gonzalez-Lugo J; Ye BH; Adrianzen Herrera DA; Sica RA; Shah U; Shah N; Kornblum N; Braunschweig I; Derman O; Mantzaris I; Shastri A; Wang Y; Verma A; Zalta B; Janakiram M
Leuk Lymphoma; 2019 Dec; 60(13):3272-3276. PubMed ID: 31204876
[TBL] [Abstract] [Full Text] [Related]
10. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.
Casasnovas RO; Bouabdallah R; Brice P; Lazarovici J; Ghesquieres H; Stamatoullas A; Dupuis J; Gac AC; Gastinne T; Joly B; Bouabdallah K; Nicolas-Virelizier E; Feugier P; Morschhauser F; Delarue R; Farhat H; Quittet P; Berriolo-Riedinger A; Tempescul A; Edeline V; Maisonneuve H; Fornecker LM; Lamy T; Delmer A; Dartigues P; Martin L; André M; Mounier N; Traverse-Glehen A; Meignan M
Lancet Oncol; 2019 Feb; 20(2):202-215. PubMed ID: 30658935
[TBL] [Abstract] [Full Text] [Related]
11. [Value of CD, MPO, Ki-67 and C-MYC Positive Rate in the Pathological Tissues and C-MYC Gene of Patients with T-LBL/ALL for Predicting Prognosis].
Wu Y; Tang HY; Ding YY; Pan XQ; Tan CM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):110-115. PubMed ID: 29397827
[TBL] [Abstract] [Full Text] [Related]
12. Natural history of t(11;14) multiple myeloma.
Lakshman A; Alhaj Moustafa M; Rajkumar SV; Dispenzieri A; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Leung N; Go RS; Lin Y; Kourelis TV; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
Leukemia; 2018 Jan; 32(1):131-138. PubMed ID: 28655925
[TBL] [Abstract] [Full Text] [Related]
13. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.
Shah V; Sherborne AL; Walker BA; Johnson DC; Boyle EM; Ellis S; Begum DB; Proszek PZ; Jones JR; Pawlyn C; Savola S; Jenner MW; Drayson MT; Owen RG; Houlston RS; Cairns DA; Gregory WM; Cook G; Davies FE; Jackson GH; Morgan GJ; Kaiser MF
Leukemia; 2018 Jan; 32(1):102-110. PubMed ID: 28584253
[TBL] [Abstract] [Full Text] [Related]
14. GLUT1-mediated selective tumor targeting with fluorine containing platinum(II) glycoconjugates.
Liu R; Fu Z; Zhao M; Gao X; Li H; Mi Q; Liu P; Yang J; Yao Z; Gao Q
Oncotarget; 2017 Jun; 8(24):39476-39496. PubMed ID: 28467806
[TBL] [Abstract] [Full Text] [Related]
15. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
Tembhare PR; Ghogale S; Ghatwai N; Badrinath Y; Kunder N; Patkar NV; Bibi AR; Chatterjee G; Arora B; Narula G; Banawali S; Deshpande N; Amare P; Gujral S; Subramanian PG
Cytometry B Clin Cytom; 2018 Jan; 94(1):100-111. PubMed ID: 27718302
[TBL] [Abstract] [Full Text] [Related]
16. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data.
International CLL-IPI working group
Lancet Oncol; 2016 Jun; 17(6):779-790. PubMed ID: 27185642
[TBL] [Abstract] [Full Text] [Related]
17. [Clinical and cytogenetic characteristics of myeloma patients with overall survival less than 24 months].
Zhuang J; Tang W; Li H; Chen M; Han B; Zhu T; Duan M; Li J; Zhang W; Xu Y; Wang S; Zhao Y; Zhou D
Zhonghua Yi Xue Za Zhi; 2015 Mar; 95(10):736-40. PubMed ID: 26080843
[TBL] [Abstract] [Full Text] [Related]
18. Chronic lymphocytic leukemia: a clinical review.
Nabhan C; Rosen ST
JAMA; 2014 Dec; 312(21):2265-76. PubMed ID: 25461996
[TBL] [Abstract] [Full Text] [Related]
19. [Long-term outcomes of childhood lymphoblastic lymphoma: report of 70 cases].
Xu Z; Pan C; Chen J; Xue HL; Ye QD; Zhou M; Luo CY; Jiang H; Li BS; Tang YJ; Wang JM; Dong L; Tang JY
Zhonghua Xue Ye Xue Za Zhi; 2013 Dec; 34(12):1044-9. PubMed ID: 24369162
[TBL] [Abstract] [Full Text] [Related]
20. Improving the quality of bone marrow assessment: Impact of operator techniques and use of a specimen preparation checklist.
Odejide OO; Cronin AM; DeAngelo DJ; Bernazzoli ZA; Jacobson JO; Rodig SJ; LaCasce AS; Mazeika TJ; Earles KD; Abel GA
Cancer; 2013 Oct; 119(19):3472-8. PubMed ID: 23921812
[TBL] [Abstract] [Full Text] [Related]
[Next]
